- Generic name
- Mesalazine [5-aminosalicylic acid]
- Strength
- 400 mg
- Dosage form
- Tablet (Delayed Release)
- Manufactured by
- Drug International Ltd.
- Therapeutic class
- Aminosalicylates
৳ 4.9 ৳ 5.00 2% off unit price
Price updated: 18 Nov 2026
Made by Drug International Ltd., Canasa is a tablet (delayed release) whose active ingredient is Mesalazine [5-aminosalicylic acid]. Mesalazine is indicated for Treatment of mild to moderately active Ulcerative Colitis & & Crohn’s Disease Maintenance of remission of Ulcerative Colitis Maintenance of remission of Crohn’s disease Ask your doctor whether it is right for your condition.
Made by Drug International Ltd., Canasa is a tablet (delayed release) whose active ingredient is Mesalazine [5-aminosalicylic acid]. Mesalamine diminishes infammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is indicated for Treatment of mild to moderately active Ulcerative Colitis & & Crohn’s Disease Maintenance of remission of Ulcerative Colitis Maintenance of remission of Crohn’s disease Use it only as your doctor directs.
Mesalazine is indicated for Treatment of mild to moderately active Ulcerative Colitis & & Crohn’s Disease Maintenance of remission of Ulcerative Colitis Maintenance of remission of Crohn’s disease Ask your doctor whether it is right for your condition.
Canasa is taken by mouth. Swallow the tablet (delayed release) with water. Do not change the dose or stop early without asking your doctor. If you miss a dose, ask your doctor or pharmacist what to do.
The commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.
It should be given in pregnancy only if the potential beneft justifes the potential risk to the fetus. Renal impairment, including minimal change nephropathy and acute and chronic interstitial nephritis has been reported in patients taking Mesalamine. Patients should have renal function monitored, prior to treatment start and then it should be monitored periodically during treatment. Keep out of reach of children.
Mesalazine is indicated for Treatment of mild to moderately active Ulcerative Colitis & & Crohn’s Disease Maintenance of remission of Ulcerative Colitis Maintenance of remission of Crohn’s disease Ask your doctor whether it is right for your condition.
Canasa is taken by mouth. Swallow the tablet (delayed release) with water.
The commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc. Tell your doctor if any side effect bothers you or does not go away.
The listed price is ৳ 5.00.
৳ 4.9 ৳ 5.00 2% off unit price
Price updated: 18 Nov 2026
The mechanism of action of Mesalamine is unknown, but appears to be topical rather than systemic. Mucosal production of Arachidonic Acid metabolites, both through the cyclooxygenase pathways, that is, prostanoids, and through the lipoxygenase pathways, that is, leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic infammatory bowel disease. Mesalamine diminishes infammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
Hypersensitivity to salicylates or to any other component of the formulation.
The commonly reported adverse events are headache, nausea, dizziness, asthenia, dyspepsia, vomiting, pruritus etc.
It should be given in pregnancy only if the potential beneft justifes the potential risk to the fetus. Caution is advised when it is administered to a nursing mother.
Store below 30 0 C. Protect from light and moisture. Keep all medicines out of the reach of children.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.